AbbVie
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell AbbVie and other ETFs, options, and stocks.About ABBV
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions.
CEORobert A. Michael
CEORobert A. Michael
Employees50,000
Employees50,000
HeadquartersNorth Chicago, Illinois
HeadquartersNorth Chicago, Illinois
Founded2011
Founded2011
Employees50,000
Employees50,000
ABBV Key Statistics
Market cap306.35B
Market cap306.35B
Price-Earnings ratio60.40
Price-Earnings ratio60.40
Dividend yield3.58%
Dividend yield3.58%
Average volume5.01M
Average volume5.01M
High today$174.92
High today$174.92
Low today$172.39
Low today$172.39
Open price$173.25
Open price$173.25
Volume5.25M
Volume5.25M
52 Week high$207.32
52 Week high$207.32
52 Week low$151.29
52 Week low$151.29
ABBV News
TipRanks 8h
AbbVie to acquire Nimble Therapeutics for $200M cash at closingAbbVie (ABBV) and Nimble Therapeutics announced a definitive agreement under which AbbVie will acquire Nimble, including its lead asset, an investigational oral...
TipRanks 4d
AbbVie to present results from two clinical trials of epcoritamabAbbVie (ABBV) announced new results from two ongoing clinical trials evaluating epcoritamab, a CD3xCD20 bispecific T-cell-engaging antibody administered subcuta...
Benzinga 4d
AbbVie's Early Parkinson's Candidate Hits Primary Goal In Pivotal Late-Stage StudyOn Monday, AbbVie Inc. ABBV revealed topline results from its pivotal Phase 3 TEMPO-2 trial, which evaluated investigational tavapadon as a flexible-dose monoth...
Analyst ratings
61%
of 31 ratingsBuy
61.3%
Hold
38.7%
Sell
0%
More ABBV News
Simply Wall St 5d
AbbVie Will Pay A Larger Dividend Than Last Year At $1.64AbbVie Inc.'s ( ) dividend will be increasing from last year's payment of the same period to $1.64 on 14th of February. This will take the dividend yield to an...
